Skip to main content

Professor Dr. Robert Schiestl Ph. D. Joins Pacific Software Inc. as Chief Science Advisor (CSA)

Written by Customer Service on . Posted in Public Companies.

DANA POINT, Calif., July 22, 2024 (GLOBE NEWSWIRE) — Pacific Software Inc.(OTC:PFSF), an emerging skincare, and aesthetics company known for its patented cosmeceutical technology Dermatrix and science-based dietary supplements, is excited to announce the appointment of Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA), effective immediately.

Dr. Robert Schiestl is a distinguished scientist who received his Ph.D. from the University of Vienna, Austria with an extensive background in molecular toxicology, cancer prevention, and genomics. He was previously Assistant and Associate Professor in the Department of Cancer Research and later Toxicology at the Harvard School of Public Health. He is currently Professor Emeritus of Pathology, Environmental Health Sciences and Radiation Oncology at UCLA. He was a Director of the UCLA Center for Environmental Genomics, member of the UCLA Cancer Center and Occupational and Environmental Health Sciences. He was also a member of the Interdepartmental Program in molecular Toxicology (advisory committee) at UCLA. Dr. Schiestl has authored over 200 peer-reviewed publications and has been recognized with numerous awards for his groundbreaking research and contributions to science.

Dr. Schiestl’s work focuses on the mechanisms of genetic stability and the development of strategies to prevent genetic diseases and cancer. His research has provided significant insights into the field of oxidative stress and its impact on health, which aligns perfectly with the company’s mission to develop innovative skincare products and science-based dietary supplements.

Dr. Schiestl’s Achievements and Contributions Include:

  • Over 200 peer-reviewed publications in prestigious scientific journals, 9 press releases and 16 patents and 6 companies.
  • Recipient of numerous awards including Outstanding Leadership Award in Healthcare 2022, Outstanding Visionary Award in Healthcare 2023, Outstanding Organization Award in Healthcare 2024, Outstanding Education Award 2023, The Outstanding MORE Leadership Award (Money and Real Estate) in 2023, Outstanding CXO Award 2024 as best CEO, the Outstanding Leadership Award in Internet 2024, The Best Speakership Award at The International Conference on Nursery, Patient Safety and Healthcare 2023.
  • Pioneering research in genetic stability and cancer prevention and Health.
  • Development of novel strategies to combat oxidative stress-related health issues.

Harrysen Mittler, CEO stated: “We are thrilled to welcome Dr. Robert Schiestl to our team as our Chief Science Advisor. His unparalleled expertise and visionary approach to scientific research will be invaluable as we continue to advance our cosmeceutical technology and dietary supplements to commercial status. His insights and guidance may play a crucial role in shaping the future of our innovations and supplement offerings.”

About Pacific Software Inc.

Pacific Software Inc. is an emerging cosmetics and aesthetics company developing skincare products featuring its patented cosmeceutical technology known as Dermatrix. Additionally, the company expects to produce science-based dietary supplements designed to promote overall health and wellness. Recently the company announced the acquisition of a science based dietary supplement supporting brain health and memory function. The supplement was sold over a period of 8 years under the brand names of SuppleMEM AD™ and A.L.Z. Defense™ featuring a formula tested extensively by leading Alzheimer’s researchers. The Company intends to resurrect these brand names and commercial product applications in the USA and Mexico.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, PFSF’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners, and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various scientific and manufacturing programs, changes in future customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond PFSF’s control. Except as may be required by law, Pacific Software, Inc. undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release.

Contact:

Harrysen Mittler, CEO
Tel: (310) 600-5064
E-mail: info@pacificsoftwareinc.com
Website: pacificsoftwareinc.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.